Delfi Diagnostics: David Morgenstern

David Morgenstern has been appointed as VP of clinical development at Delfi Diagnostics. He joins the cancer liquid biopsy company from Roche Diagnostics, where he was most recently head of clinical development for oncology and genetics. Prior to that, he led clinical affairs at pharmaceutical company Endocyte, and before that, he managed clinical studies at Merck. Morgenstern holds a PhD in microbiology and immunology from Indiana University.